CanSino Biologics Inc.
CanSino Biologics is a Tianjin-based vaccine developer listed in both Hong Kong (HKEX: 6185) and Shanghai (SSE: 688185). Its quadrivalent meningococcal conjugate vaccine Menhycia (MCV4) is approved in China.
| Headquarters | Tianjin, China |
|---|---|
| Listing | HKEX:06185; SSE:688185 |
| Lead asset / stage | Menhycia (MCV4) Approved — China |
| Latest event | CanSinoBIO announced participation in the WHO global polio vaccine consultation. |